- Stocks
- Pharma & Healthcare
- Novartis India
Novartis India share price
NSE: NOVARTINDPharma & HealthcareDrug Manufacturers - Specialty & Generic
Novartis India at a glance
Novartis India (NSE: NOVARTIND) closed at ₹1,848.00 on 21 Oct 2026. With a market capitalisation of ₹3,429 Cr, it ranks 892nd by market cap among the 3,928 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 12.9% in FY25. Its 52-week range is ₹950.00 (24 Apr 2026) to ₹2,588.80 (10 Sep 2026); the last close is 28.6% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹104 Cr (+18.6% year on year) and net profit ₹32 Cr (+16.6%), on a standalone basis. Promoters held 70.68% of the company as of 31 Jul 2026.
Key numbers
- Market cap
- ₹3,429 CrRank 892 on NSE
- Price to book
- 2.47×FY25
- EPS (TTM)
- ₹39.61to Q1 FY27
- ROE
- 12.9%FY25
- ROCE
- 16.3%FY25
- Debt to equity
- 0FY25
- Net profit margin
- 28.3%FY25
- Book value / share
- ₹318.06FY25
- Dividend payout
- 61.2%FY25
- 52-week high
- ₹2,588.8010 Sep 2026
- 52-week low
- ₹950.0024 Apr 2026
Returns to —
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Novartis India quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹87 Cr | ₹93 Cr | ₹84 Cr | ₹88 Cr | ₹90 Cr | ₹86 Cr | ₹91 Cr | ₹104 Cr |
| Revenue YoY | +10.6% | +10.0% | +3.3% | −5.1% | +3.7% | −7.6% | +8.0% | +18.6% |
| Net profit | ₹20 Cr | ₹25 Cr | ₹29 Cr | ₹28 Cr | ₹24 Cr | ₹16 Cr | ₹25 Cr | ₹32 Cr |
| Net profit YoY | −13.8% | −4.2% | +99.6% | +7.3% | +18.7% | −36.8% | −13.8% | +16.6% |
| Net margin | 23.4% | 27.4% | 34.9% | 31.5% | 26.8% | 18.7% | 27.9% | 31.0% |
| EPS | ₹8.27 | ₹10.31 | ₹11.87 | ₹11.19 | ₹9.81 | ₹6.52 | ₹10.23 | ₹13.05 |
Novartis India financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹438 Cr | ₹381 Cr | ₹400 Cr | ₹379 Cr | ₹335 Cr | ₹356 Cr |
| Operating profit | ₹29 Cr | ₹40 Cr | ₹46 Cr | ₹115 Cr | ₹123 Cr | ₹130 Cr |
| Net profit | ₹10 Cr | ₹21 Cr | −₹4 Cr | ₹103 Cr | ₹85 Cr | ₹101 Cr |
| EPS (₹) | ₹4.08 | ₹8.46 | −₹1.51 | ₹41.86 | ₹34.50 | ₹40.87 |
| Cash from operations | −₹23 Cr | −₹69 Cr | ₹39 Cr | ₹45 Cr | ₹113 Cr | ₹75 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹721 Cr | ₹711 Cr | ₹692 Cr | ₹776 Cr | ₹745 Cr | ₹785 Cr |
Novartis India shareholding pattern
| Holder | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 | 31 Jul 2026 |
|---|---|---|---|---|---|---|
| Promoters | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% | 70.68% |
| Foreign institutions | 0.19% | 0.19% | 0.19% | 0.17% | 0.16% | 0.15% |
| Domestic institutions | 0.53% | 0.53% | 0.64% | 0.53% | 1.36% | 1.39% |
| Non-institutions | 28.60% | 28.60% | 28.50% | 28.61% | 27.80% | 27.78% |
Novartis India vs peers
The listed Pharma & Healthcare companies nearest to Novartis India by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| RPGLIFERPG Life Sciences | — | — | — | ₹3,766 Cr | — | — |
| GUFICBIOGufic Biosciences | — | — | — | ₹3,562 Cr | — | — |
| SMSPHARMASMS Pharmaceuticals | — | — | — | ₹3,545 Cr | — | — |
| NOVARTINDNovartis India | — | — | — | ₹3,429 Cr | — | — |
| AARTIDRUGSAarti Drugs | — | — | — | ₹3,380 Cr | — | — |
| PANACEABIOPanacea Biotec | — | — | — | ₹3,285 Cr | — | — |
| UNICHEMLABUnichem Laboratories | — | — | — | ₹3,128 Cr | — | — |
Ask anything about Novartis India
Pivot answers on the live chart with evidence you can check, and tests strategies against NOVARTIND's own history. Try: “Why has NOVARTIND moved over the last three months?” · “Backtest a 50-day moving-average crossover on NOVARTIND over five years” · “Compare NOVARTIND with RPGLIFE on margins and valuation”
Frequently asked questions about Novartis India
What is the share price of Novartis India today?
Novartis India (NSE: NOVARTIND) last closed at ₹1,848.00 on 21 Oct 2026. Its 52-week high is ₹2,588.80 and its 52-week low is ₹950.00.
What is the market cap of Novartis India?
Novartis India's market capitalisation is ₹3,429 Cr (₹3,429 Cr) at the — close, ranking 892nd among the NSE companies Pivot tracks.
What is the ROE and ROCE of Novartis India?
Return on equity was 12.9% in FY25 and return on capital employed was 16.3% in FY25 (standalone figures).
Is Novartis India a debt-free company?
Novartis India is close to debt-free: its debt-to-equity ratio was 0 in FY25.
What were Novartis India's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Novartis India reported revenue of ₹104 Cr, +18.6% year on year, and net profit of ₹32 Cr, +16.6% year on year.
What is the shareholding pattern of Novartis India?
As of 31 Jul 2026: promoters 70.68%, foreign institutions 0.15%, domestic institutions 1.39%, non-institutions 27.78%.
Who are Novartis India's competitors?
The listed Pharma & Healthcare companies closest to Novartis India by market cap are RPG Life Sciences, Gufic Biosciences, SMS Pharmaceuticals, Aarti Drugs, Panacea Biotec and Unichem Laboratories.
Is Novartis India a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Novartis India's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NOVARTIND against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 21 Oct 2026. Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 3,928 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with N · all NSE stocks · this page as text